Intractability of Complex Partial Seizure with Secondary Generalization: Kindling Studies in Cats

Total Page:16

File Type:pdf, Size:1020Kb

Intractability of Complex Partial Seizure with Secondary Generalization: Kindling Studies in Cats Tohoku J. Exp. Med., 1990, 161, Suppl., 253-271 Intractability of Complex Partial Seizure with Secondary Generalization: Kindling Studies in Cats MITSUMOTOSATO Department of Neuropsychiatry, Okayama University Medical School, Okayama 700 SATO, M. Intractability of Complex Partial Seizure with Secondary Generali- zation: Kindling Studies in Cats. Tohoku J. Exp. Med., 1990, 161, Suppl., 253- 271•\Among many factors linked to an intractability of partial seizure secon- darily generalized, changes in the brain resulting from repeated epileptic seizures are discussed mainly in light of our evidence obtained from kindling studies in cats. In addition, the literatures on biological mechanisms of the kindling effect are reviewed briefly. The evidence demonstrated and reviewed here indicates that: 1) limbic structure is not susceptable to develop generalized convulsions initially, 2) repeated attacks of limbic seizures result in a profound reduction in seizure threshold at the primary epileptogenic focus in the limbic structures, 3) once a limbic seizure developed to secondarily generalized convulsion, it seldom changes into the original partial seizure, 4) kindled events in the limbic structures are more profound and persistent than that in the cerebral cortex, and 5) repetition of focal cortical or limbic seizures may eventually produce spontaneous convulsive seizures originating in the limbic structures. These findings strongly suggest that the limbic system, rather than the cerebral cortex, is more susceptible to a lasting functional change resulted from seizure repetition, which can lead to an intractability of epilepsy with partial seizure. Lasting changes in the cell mem- brane including long-lasting enhancement of inositol phospholipid hydrolysis of the amygdala stimulated by excitatory amino acid appear important for develop- ment of trans-synaptic changes underlying the kindling-induced seizure susceptibil- ity.•\intractability; limbic seizure; focal cortical seizure; secondary sei- zure generalization; kindling mechanism Epilepsy is one of the most common neurological diseases with an incidence estimated to be between 0.3 to 0.5%. Some epileptic patients suffer from intractability of epileptic seizures. Many factors that lead to a poor prognosis of epilepsy have been documented except for progressive excerbation of some under- lying neurological diseases. Rodin (1968) described 4 factors linked to poor prognosis : 1) partial or mixed seizure types, 2) presence of an abnormal neur- ological or mental state, 3) low IQ, and 4) increase in the number of seizures and duration of epilepsy before referral. Reynolds and others (1983) reported that Present address and reprints requests to : Mitsumoto Sato, Department of Neurop- sychiatry,`Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku 980, Sendai, Japan. 253 254 M. Sato there was less certainty about the influence of age of onset of epilepsy, of EEG abnormalities, and of genetic factors. The factor that the seizure type links to an intractability of epilepsy has been confirmed by a Japanese epilepsy study group in 1981 (Okuma and Kumashiro). According to the data on seizure control, the remission rates for partial seizures with secondary generalization and some of the combined seizure types such as elementary and complex partial seizures with generalized tonic-clonic seizures were significantly lower than the mean remission rate of seizures overall (Table 1). With regards to the number of seizures and duration of epilepsy as a poor prognostic factor, Gowers (1881) has stated : "when one attack has occurred, whether in apparent consequence of an immediate excitant or not, others usually follow without any immediate traceable cause. The effect of a convulsion on the nerve centres is such as to render the occurrence of another more easy, to intensify the predisposition that already exists. Thus every fit may be said to be, in part, the result of those which have preceded it, the cause of those which follow it "(Reynolds et al.1983). The following evidence that support this Gowers' hypothesis has been available thereafter. Firstly, there are reports of spontane- ous convulsions that appeared in non-epileptic patients with schizophrenia after repeated electroconvulsive therapy too many times. In fact, more than 200 such cases have been reported by at least 14 authors (Sato and Wada 1975). As an example, Naoi (1959) has reported 35 cases with spontaneous convulsive seizures out of 172 schizophrenic patients who had been treated with electroconvulsive therapy : 26 out of these 35 cases had received the therapy more than 50 times. Secondly, the occurrence of spontaneous convulsions as well as an augmented TABLE.1 Outcome of seizure control Remission means disappearance of seizure for more than 3 years. GTC, generalized tonic-clonic convulsion ; n, number of subjects (Okuma and Kumashiro 1981). Epilepsy and Kindling 255 epileptic response after repeated electroconvulsive seizures has been reported in animal experiments by several authors (Alonso-de Florida and Delgado 1958 ; Delgado 1959; Delgado and Sevillano 1961; Herberg and Watkins 1966). God- dard and others (1969) investigated such phenomenon systematically and used the term kindling effect to describe the phenomenon. The kindling effect seems to be an adequate animal model to study the Gowers' hypothesis. Kindling effect and its transference phenomenon The kindling effect is a process whereby repeated induction of local epileptic manifestation results in long-term changes in neural organization, and when repeated many times, eventually results in generalized convulsions (Goddard et al. 1969 ; Racine 1972) and spontaneous seizures (Goddard and Douglas 1976 ; Wada et al. 1974). The kindled events which include readiness for kindled generalized convulsions and produced interictal spike discharges persist for one year without further stimulation (Wada et al. 1974). Related to kindling is the phenomenon called transference, which is a significant saving of kindling stimuli required for re-kindling at a secondary brain site following a primary brain site kindling. Transfer of the primary site kin- dling to a secondary site was confirmed after removal of the primarily kindled brain site (Racine 1972). Accordingly, this phenomenon presumably based on a trans-synaptic change from the primarily kindled site to the secondary site. Moreover, the kindling transfer was found to occur after a 14 day interval between the end of the primary site kindling and the beginning of the secondary site re-kindling (McIntyre and Goddard 1973). These findings indicate that the kindling-induced functional change in the secondary brain site lasts at least for 2 weeks, and is independent of the change in the primary site. The necessary conditions for kindling are recurrent appearance of after-discharges (AD) with an adequate intertrial interval (Racine 1978). Repeated administration of a stimu- lus which intensity is insufficient to produce an AD can not preduce kindling, and repeated stimulations applied at less than 20 min interval often produce adapta- tion rather than kindling (Goddard and Douglas 1976). Thus, it is clear that repeated induction of localized AD results in a lasting increase in seizure suscepti- bility in the brain which presumably based upon a trans-synaptic change originat- ing in the primary epileptogenic focus. General procedures A series of our data described here are restricted to those obtained from kindling in cats. The kindling stimulus was one sec trains of a 60-Hz sine wave at an intensity minimal to produce AD. In kindling session, the kindling stimu- lus was delivered once daily until generalized convulsions were produced on 5 consecutive days. After 7 days from the last convulsion, re-kindling from a secondary brain site was started to examine the transference phenomenon. Our 256 M. Sato previous classification of seizure stages in amygdaloid (Wada and Sato 1974), hippocampal (Sato 1975), septal (Sato 1976, 1980) and Sylvian gyrus (Sato et al. 1980b) kindling in cats was used to assess chronological changes in behavioral seizure manifestations during kindling and re-kindling sessions. Behavioral observation with simultaneous EEG recording was performed before and after each daily stimulation and during spontaneous seizures. Which is more susceptible to produce generalized convulsions, the cerebral cortex or limbic structures ? A one-sec stimulation of one mA intensity was delivered to the sylvian gyrus and limbic structures to examine the first trial generalized convulsions. The first trial generalized convulsions were observed in 5 of 9 cats after Sylvian gyrus stimulation (Table 2). No epileptic response or partial seizure was produced in the other 4 cats. On the contrary, when the amygdala, hippocampus and septum were stimulated, no generalized convulsion was produced in any of the 15 cats examined (Ebara et al., unpublished). This result shows that the Sylvian gyrus is more susceptible to the first trial generalized convulsions than limbic structures when high current stimu- lation was applied. In other word, the limbic structures are less susceptible to produce generalized convulsion than the cerebral cortex, initially. The progres- sive development of partial limbic seizure to secondarily generalized convulsions after seizure repetition may depend upon increased functional connections (God- dard 1981) between the kindled limbic structure and the cerebral motor cortex. Tanaka (1977) reported the appearance
Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,822,539 B2 Jensen (45) Date of Patent: Sep
    USOO8822.539B2 (12) United States Patent (10) Patent No.: US 8,822,539 B2 Jensen (45) Date of Patent: Sep. 2, 2014 (54) COMBINATION THERAPIES: INHIBITORS Bialer et al., “Progress report on new antiepileptic drugs: a Summary OF GABA TRANSAMINASE AND NKCC1 of the Seventh Eilat Conference (EILATVII).” Epilepsy Res., 61:1- 48, 2004 (Abstract only). (75) Inventor: Frances E. Jensen, Boston, MA (US) Clift and Silverman, “Synthesis and Evaluation of Novel Aromatic Substrates and Competitive Inhibitors of GABA Aminotransferase.” (73) Assignee: Children's Medical Center Bioorg. Med. Chem. Left., 18:3122-3125, 2008. Crewther et al., “Potassium Channel and NKCC Cotransporter Corporation, Boston, MA (US) Involvement in Ocular Refractive Control Mechanisms. PlosOne, 3:e2839, 2008. (*) Notice: Subject to any disclaimer, the term of this Cubells et al., “In vivo action of enzyme-activated irreversible inhibi patent is extended or adjusted under 35 tors of glutamic acid decarboxylase and gamma-aminobutyric acid U.S.C. 154(b) by 149 days. transaminase in retina vs. brain.” J. Pharmacol. Exp. Ther. 238:508 514, 1986 (Abstract only). (21) Appl. No.: 13/069,311 Duboc et al., “Vigabatrin, the GABA-transaminase inhibitor, dam ages cone photoreceptors in rats.” Ann. Neurol. 55:695-705, 2004 (22) Filed: Mar 22, 2011 (Abstract only). Dzhala et al., “Bumetanide enhances phenobarbital efficacy in a (65) Prior Publication Data neonatal seizure model.” Ann. Neurol. 63:222-235, 2008 (Abstract US 2011/0237554 A1 Sep. 29, 2011 only). Dzhala et al., “NKCC1 transporter facilitates seizures in the devel oping brain.” Nature Med., 11:1205-1213, 2005 (Abstract only). Follett et al., “Glutamate Receptor-Mediated Oligodendrocyte Tox Related U.S.
    [Show full text]
  • The Syntheses of Β-Lactam Antibiotics from 3-Formylcephalosporins As the Key-Intermediates
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/19082 Please be advised that this information was generated on 2021-10-03 and may be subject to change. The Syntheses of β-Lactam Antibiotics from 3-Formylcephalosporins as the Key-intermediates Een wetenschappelijke proeve op het gebied van de Natuurwetenschappen, Wiskunde en Informatica Proefschrift ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen, volgens besluit van het College van Decanen in het openbaar te verdedigen op woensdag 6 februari 2002 des namiddags om 1.30 uur precies door Rolf Keltjens Geboren op 9 april 1972 te Horst Promotor Prof. dr. B. Zwanenburg Copromotor Dr. A.J.H. Klunder Manuscriptcommissie Dr. E. de Vroom (DSM Anti-Infectives, Delft) Dr. J. Verweij (voorheen DSM Anti-Infectives, Delft) Prof. dr. ir. J.C.M. van Hest The research described in this PhD thesis was part of the Cluster Project "Fine- Chemistry" and was financially supported by DSM (Geleen, The Netherlands) and the Dutch Ministry of Economical Affairs (Senter). ISBN 90-9015389-6 Omslag: Penicillium chrysogenum (copyright DSM N.V.) "Experiment is the sole interpreter of the artifices of Nature" Leonardo da Vinci (1452-1519) Aan mijn ouders Paranimfen René Gieling Sander Hornes VOORWOORD Als het manuscript nagenoeg gereed is en het geheel klaar is voor verzending naar de drukker, is het ook de hoogste tijd om de mensen met wie je vier jaar lang intensief hebt samengewerkt te bedanken.
    [Show full text]
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC
    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
    [Show full text]
  • Light and Electron Microscope Evidence for Involvement of Neuroglia (Cerebellum/Cyclic AMP/Y-Aminobutyric Acid/Harmaline/Diazepam) V
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 3, pp, 1485-1488, March 1979 Neurobiology Immunocytochemical localization of cyclic GMP: Light and electron microscope evidence for involvement of neuroglia (cerebellum/cyclic AMP/y-aminobutyric acid/harmaline/diazepam) V. CHAN-PALAY* AND S. L. PALAYt Departments of *Neurobiology and tAnatomy, Harvard Medical School, Boston, Massachusetts 02115 Contributed by Sanford L. Palay, December 7, 1978 ABSTRACT Guanosine 3',5'-cyclic monophosphate (cGMP) presents cytopharmacological evidence from immunocyto- immunoreactivity in the rat's cerebellum was studied with light chemistry for the cellular and subcellular location of cGMP in and electron microscopy by the indirect fluorescence method some cerebellar neurons and particularly in neuroglial cells. and the peroxidase-antiperoxidase method. Labeled cells in- cluded neuroglial cells in the cerebellar cortex, white matter, and deep nuclei; some stellate and basket cells in the cortex; and MATERIALS AND METHODS some large neurons in the deep nuclei. No evidence was found Adult 200-300 g Sprague-Dawley rats, the indirect immu- for sagittal microzonation in the cGMP distribution. In the la- nofluorescence method (11), and the peroxidase-antiperoxidase beled cells, cGMP immunoreactive sites were localized to sur- face membranes, organelles, and the cytoplasmic matrix. (PAP) method (12) for light and electron microscopy were used. Specificity was indicated by the same pattern of labeling after Rabbit antisera were raised against the 2'-O-succinyl derivative treatment with cGMP immunoglobulin that had been adsorbed of cGMP or cAMP conjugated to limpet hemocyanin (13). More with adenosine 3',5'-cyclic monophosphate (cAMP) and by the than 50% of 2'-O-succinyl-cGMP ([125I]iodotyrosine methyl failure to label after treatment with normal rabbit sera or with ester derivative) or 2'-O-succinyl-cAMP ([1251]iodotyrosine cGMP immunoglobulin that had been adsorbed with 1 mM methyl ester derivative) (<0.01 pmol) was bound at a serum cGMP.
    [Show full text]
  • Increase in the Bmax of Y-Aminobutyric Acid-A Recognition Sites in Brain Regions of Mice Receiving Diazepam
    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 2247-2251, April 1984 Neurobiology Increase in the Bmax of y-aminobutyric acid-A recognition sites in brain regions of mice receiving diazepam (muscimol/-aminobutyric acid receptors/benzodiazepine receptors/locomotor activity) P. FERRERO, A. GuIDOTTI, AND E. COSTA* Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, DC 20032 Contributed by E. Costa, December 12, 1983 ABSTRACT y-Aminobutyric acid (GABA) receptors were MATERIALS AND METHODS characterized in vivo by studying ex vivo the binding of [3H]Muscimol (New England Nuclear) labeled on the meth- [3H]muscimol to cerebellum, cortex, hippocampus, and cor- ylene side-chain (specific activity, 29.4 Ci/mmol; 1 Ci = 37 pus striatum of mice receiving intravenous injections of tracer GBq) was injected into the tail vein of female mice (20-25 g). doses of high-specific-activity (-30 Ci/mmol) [3H]muscimol. Routinely, the dose of [3H]muscimol injected was 5 uCi per This ligand binds with high affinity (apparent Kd, 2-3 x 10-9 20 g of body weight in 0.2 ml of saline. This radiolabeled M) to a single population of binding sites (apparent Bmax, 250- ligand dose was administered either alone or with various 180 fmol per 10 mg of protein). Pharmacological studies using doses of unlabeled muscimol. In some experiments, drugs that selectively bind to GABAA or GABAB receptors [3H]muscimol was injected into cerebral ventricles through a suggest that [3H]muscimol specifically labels a GABAA recog- polyethylene cannula chronically implanted (13). The dissec- nition site. Moreover, diazepam (1.5 ,umol/kg, i.p.) increases tion of the different brain areas (cerebellum, cortex, stria- the Bmax but fails to change the affinity of [3Hlmuscimol bind- tum, and hippocampus) was carried out on a chilled (00C) ing to different brain areas.
    [Show full text]
  • Pharmacological Studies on a Locust Neuromuscular Preparation
    J. Exp. Biol. (1974). 6i, 421-442 421 *&ith 2 figures in Great Britain PHARMACOLOGICAL STUDIES ON A LOCUST NEUROMUSCULAR PREPARATION BY A. N. CLEMENTS AND T. E. MAY Woodstock Research Centre, Shell Research Limited, Sittingbourne, Kent {Received 13 March 1974) SUMMARY 1. The structure-activity relationships of agonists of the locust excitatory neuromuscular synapse have been reinvestigated, paying particular attention to the purity of compounds, and to the characteristics and repeatability of the muscle response. The concentrations of compounds required to stimu- late contractions of the retractor unguis muscle equal in force to the neurally evoked contractions provided a measure of the relative potencies. 2. Seven amino acids were capable of stimulating twitch contractions, glutamic acid being the most active, the others being analogues or derivatives of glutamic or aspartic acid. Aspartic acid itself had no excitatory activity. 3. Excitatory activity requires possession of two acidic groups, separated by two or three carbon atoms, and an amino group a to a carboxyl. An L-configuration appears essential. The w-acidic group may be a carboxyl, sulphinyl or sulphonyl group. Substitution of any of the functional groups generally causes total loss of excitatory activity, but an exception is found in kainic acid in which the nitrogen atom forms part of a ring. 4. The investigation of a wide variety of compounds revealed neuro- muscular blocking activity among isoxazoles, hydroxylamines, indolealkyl- amines, /?-carbolines, phenazines and phenothiazines. No specific antagonist of the locust glutamate receptor was found, but synaptic blocking agents of moderately high activity are reported. INTRODUCTION The study of arthropod neuromuscular physiology has been impeded by the lack of an antagonist which can be used to block excitatory synaptic transmission by a specific postsynaptic effect.
    [Show full text]
  • Toxicol Rev 2004; 23 (1): 21-31 GHB SYMPOSIUM 1176-2551/04/0001-0021/$31.00/0
    Toxicol Rev 2004; 23 (1): 21-31 GHB SYMPOSIUM 1176-2551/04/0001-0021/$31.00/0 2004 Adis Data Information BV. All rights reserved. γ-Butyrolactone and 1,4-Butanediol Abused Analogues of γ-Hydroxybutyrate Robert B. Palmer1,2 1 Toxicology Associates, Prof LLC, Denver, Colorado, USA 2 Rocky Mountain Poison & Drug Center, Denver, Colorado, USA Contents Abstract ................................................................................................................21 1. Clinical Effects .......................................................................................................23 2. Diagnosis and Management ..........................................................................................25 3. Withdrawal ..........................................................................................................26 4. Conclusion ..........................................................................................................29 Abstract γ-Hydroxybutyrate (GHB) is a GABA-active CNS depressant, commonly used as a drug of abuse. In the early 1990s, the US Drug Enforcement Administration (DEA) warned against the use of GHB and restricted its sale. This diminished availability of GHB caused a shift toward GHB analogues such as γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) as precursors and surrogates. Both GBL and 1,4-BD are metabolically converted to GHB. Furthermore, GBL is commonly used as a starting material for chemical conversion to GHB. As such, the clinical presentation and management of GBL and 1,4-BD
    [Show full text]
  • Safety Review of Gamma-Aminobutyric Acid (GABA)
    nutrients Review United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA) Hellen A. Oketch-Rabah 1,*, Emily F. Madden 1, Amy L. Roe 2 and Joseph M. Betz 3 1 U.S. Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, USA; [email protected] 2 The Procter & Gamble Company, Cincinnati, OH 45202, USA; [email protected] 3 Office of Dietary Supplements, National Institutes of Health, Bethesda, MD 20892, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-301-230-3249 Abstract: Gamma-amino butyric acid (GABA) is marketed in the U.S. as a dietary supplement. USP conducted a comprehensive safety evaluation of GABA by assessing clinical studies, adverse event information, and toxicology data. Clinical studies investigated the effect of pure GABA as a dietary supplement or as a natural constituent of fermented milk or soy matrices. Data showed no serious adverse events associated with GABA at intakes up to 18 g/d for 4 days and in longer studies at intakes of 120 mg/d for 12 weeks. Some studies showed that GABA was associated with a transient and moderate drop in blood pressure (<10% change). No studies were available on effects of GABA during pregnancy and lactation, and no case reports or spontaneous adverse events associated with GABA were found. Chronic administration of GABA to rats and dogs at doses up to 1 g/kg/day showed no signs of toxicity. Because some studies showed that GABA was associated with decreases Citation: Oketch-Rabah, H.A.; in blood pressure, it is conceivable that concurrent use of GABA with anti-hypertensive medications Madden, E.F.; Roe, A.L.; Betz, J.M.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,040,552 B2 Arnelle Et Al
    US009040552B2 (12) United States Patent (10) Patent No.: US 9,040,552 B2 Arnelle et al. (45) Date of Patent: May 26, 2015 (54) SELECTIVE OPIOID COMPOUNDS Cancer online, retrieved on Jul. 6, 2007. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>.* (71) Applicant: Alkermes, Inc. Cancer online, retrieved on Jul. 6, 2007. Retrieved from the internet, URL: http://en.wikipedia.org.wiki|Cancer.* (72) Inventors: Derrick Arnelle, Arlington, MA (US); Irritable Bowel Syndrome online). Retrieved on Nov. 4, 2014 from Daniel Deaver, Franklin, MA (US); the internet. URL http://digestive.niddk.nih.gov/ddiseases/pubs/ Reginald L. Dean, III, Boxborough, bSt. MA (US); Mark Todtenkopf, Franklin, MA (US) * cited by examiner (73) Assignee: Alkermes, Inc., Waltham, MA (US) Primary Examiner — Shawquia Jackson *) Notice: Subject to anyy disclaimer, the term of this (74) Attorney, Agent, or Firm — Elmore Patent Law Group, patent is extended or adjusted under 35 U.S.C. 154(b) by 97 days. P.C.; Roy P. Issac; Carolyn S. Elmore (21) Appl. No.: 13/693,662 (57) ABSTRACT (22) Filed: Dec. 4, 2012 The present invention relates to compounds of Formula I or II, (65) Prior Publication Data or pharmaceutically acceptable salts, esters, or prodrugs US 2014/OOO5215A1 Jan. 2, 2014 thereof: Related U.S. Application Data (62) Division of application No. 12/371,334, filed on Feb. (I) 13, 2009, now Pat. No. 8,354,534. (60) Provisional application No. 61/028,780, filed on Feb. 14, 2008, provisional application No. 61/087,295, filed on Aug. 8, 2008. (51) Int.
    [Show full text]
  • Internal Aeration and Respiration of Submerged Tomato Hypocotyls Is Enhanced by Ethylene‐Mediated Aerenchyma Formation And
    Internal aeration and respiration of submerged tomato hypocotyls is enhanced by ethylene-mediated aerenchyma formation and hypertrophy Mignolli Francescoa,c, Juan Santiago Todarob and María Laura Vidoza,c,* aInstituto de Botánica del Nordeste (IBONE), UNNE-CONICET, Corrientes, Argentina bFacultad de Medicina, Universidad Nacional del Nordeste (UNNE), Corrientes, Argentina cFacultad de Ciencias Agrarias, Universidad Nacional del Nordeste (UNNE), Corrientes, Argentina Correspondence *Corresponding author, e-mail: [email protected] With the impending threat that climate change is imposing on all terrestrial ecosystems, plants’ ability to adjust to changing environments is, more than ever, a very desirable trait. Tomato (Solanum lycopersicum L.) plants display a number of responses that allow them to survive under different abiotic stresses such as flooding. We focused on understanding the mechanism that facilitates oxygen diffusion to submerged tissues and the impact it has on sustaining respiration levels. We observed that, as flooding stress progresses, stems increase their diameter and internal porosity. Ethylene triggers stem hypertrophy by inducing cell wall loosening genes, and aerenchyma formation seems to involve programmed cell death mediated by oxygen peroxide. We finally assessed whether these changes in stem morphology and anatomy are indeed effective to restore oxygen levels in submerged organs. We found that aerenchyma formation and hypertrophy not only increase oxygen diffusion towards the base of the plant but also result in an augmented respiration rate. We consider that this response is crucial to maintain adventitious root development under such conditions and, therefore, making it possible for the plant to survive when the original roots die. Introduction This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • 1 Production and Actions of Hydrogen Sulfide, A
    JPET Fast Forward. Published on February 26, 2009 as DOI: 10.1124/jpet.108.149963 JPET FastThis Forward.article has not Published been copyedited on and February formatted. The26, final 2009 version as DOI:10.1124/jpet.108.149963may differ from this version. JPET #149963 PRODUCTION AND ACTIONS OF HYDROGEN SULFIDE, A NOVEL GASEOUS BIOACTIVE SUBSTANCE, IN THE KIDNEYS Downloaded from Min Xia, Li Chen, Rachel W. Muh, Pin-Lan Li, Ningjun Li Department of Pharmacology & Toxicology, jpet.aspetjournals.org Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 (M.X, L.C., R.W.M., P.L.L., N.L.) at ASPET Journals on October 2, 2021 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on February 26, 2009 as DOI: 10.1124/jpet.108.149963 This article has not been copyedited and formatted. The final version may differ from this version. JPET #149963 Running Title: Hydrogen sulfide and renal function Send Correspondence to: Dr. Ningjun Li Department of Pharmacology & Toxicology Medical College of Virginia Virginia Commonwealth University PO Box 980613 Richmond, VA 23298 Downloaded from Phone: 804 828-4562 Fax: 804 828-4794 E-mail: [email protected] jpet.aspetjournals.org Number of text pages: 14 Number of tables: 2 Number of figures: 5 Number of references: 40 Words in the Abstract: 246 at ASPET Journals on October 2, 2021 Introduction: 325 Discussion: 1418 List of nonstandard abbreviations: H2S, hydrogen sulfide; L-Cys, L-cysteine; CBS, cystathionine β-synthetase; CGL, cystathionine γ-lyase; AOAA, aminooxyacetic acid; PPG, propargylglycine; GFR, glomerular filtration rate; U·V, urinary volume; UNa·V, urinary sodium; UK·V, urinary potassium; FF, fractional filtration; FENa, fractional excretion of sodium; FEK, fractional excretion of potassium; NHE, Na+/H+ exchanger; NKCC, Na+/K+/2Cl- cotransporter; NCC, Na+/Cl- cotransporter; ENaC, epithelial Na+ channel; NKA, Na+/K+-ATPase; CA Carbonic Anhydrase.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Aminooxyacetic Acid (hydrochloride) Item No. 28298 CAS Registry No.: 2921-14-4 Formal Name: 2-(aminooxy)-acetic acid, hemihydrochloride Synonym: Aminooxyacetate O MF: C2H5NO3 • 1/2HCl O FW: 109.3 HO NH2 Purity: ≥95% • 1/2HCl Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Aminooxyacetic acid (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the aminooxyacetic acid (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Aminooxyacetic acid (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of aminooxyacetic acid (hydrochloride) in these solvents is approximately 5 and 2 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of aminooxyacetic acid (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of aminooxyacetic acid (hydrochloride) in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Aminooxyacetic acid is a GABA transaminase (GABA-T) inhibitor (Ki = 9.16 μM) that induces GABA accumulation in the brain.1 It also inhibits cystathionine β synthase (CBS) and cystathionine γ lyase 2 (CSE; IC50s = 8.5 and 1.1 μM, respectively).
    [Show full text]